Business Context and Reporting Period
This Form 8-K, filed on September 18, 2007, reports on HAPC, Inc. (the Registrant) and its proposed acquisition of InfuSystem, Inc. The filing details the execution of Amendment No. 4 to the Stock Purchase Agreement originally dated September 29, 2006, between HAPC, Iceland Acquisition Subsidiary, Inc., InfuSystem, and I-Flow Corporation.
Key Financial Metrics and Transaction Terms
- Revised Purchase Price: The total consideration for InfuSystem was reduced from $140,000,000 to $100,000,000, subject to working capital adjustments.
- Payment Structure: The $100,000,000 base price is payable at closing via cash and/or a secured promissory note. The cash portion is $85,000,000 less any amounts paid to HAPC shareholders exercising conversion rights. The promissory note principal is $15,000,000 plus the shareholder return amount.
- Earn-Out Provision: A contingent payment of up to $12,000,000 is based on HAPC's audited consolidated net revenues for fiscal year 2010.
- Earn-Out Triggers:
- No payment if FY 2010 revenues are less than 2.744 times InfuSystem's 2007 net revenues (excluding ON-Q product line).
- Full $12,000,000 payment if FY 2010 revenues equal or exceed 3.375 times InfuSystem's 2007 net revenues.
- Pro-rata payment between $3,000,000 and $12,000,000 for revenues between the two targets.
- Fees and Expenses:
- Ticking Fee: Approximately $1,042 to $2,083 per day from September 29, 2006, until closing or termination.
- Facility Fee: $1,375,000 plus 2.5% of the promissory note principal exceeding $15,000,000, payable at closing if the note is executed.
- Reimbursement: HAPC must reimburse I-Flow for out-of-pocket expenses related to the Amendment by the earlier of closing or October 31, 2007.
Material Changes Versus Prior Period
The primary material change is the reduction of the base purchase price from $140,000,000 to $100,000,000. Additionally, the transaction structure was altered to include a performance-based earn-out of up to $12,000,000, replacing the previous fixed consideration model. The termination date for the agreement was extended from October 1, 2007, to October 22, 2007.
Outlook, Risks, and Contingencies
- Change in Control: If HAPC undergoes a change in control (merger, reorganization, or sale of assets) without I-Flow's consent or assumption of obligations by the successor, the maximum $12,000,000 earn-out becomes immediately due and payable.
- Assignment Restrictions: HAPC cannot assign the obligation to make the earn-out payment to a third party without I-Flow's prior consent.
- Transaction Timeline: The deal faces a hard deadline of October 22, 2007, for closing, or the agreement may be terminated by either party.
- Financial Statements: This filing does not contain audited financial statements, revenue, profit, or cash flow data for HAPC or InfuSystem. Investors are directed to the Definitive Proxy Statement and Supplement for detailed financial information.
Key Facts for Investor Verification
- Verify the specific calculation of InfuSystem's 2007 net revenues excluding the ON-Q product line to understand the earn-out baseline.
- Confirm the status of HAPC's financing to determine if the promissory note will be issued or if the cash portion will be fully funded.
- Review the Definitive Proxy Statement and Supplement filed on August 8 and September 18, 2007, for detailed financial data and director interests.
- Monitor the October 22, 2007, deadline for the closing of the acquisition.
- Assess the impact of the $12,000,000 contingent liability on HAPC's future cash flow projections.